Skip to main content
. 2020 May 19;7:213. doi: 10.3389/fvets.2020.00213

Table 2.

Estimated non-compartmental pharmacokinetic parameters (mean ± SD) based on time vs. plasma flunixin and 5-OH concentration profiles after single (trial 3) and multiple (trial 4) doses of flunixin meglumine administered intravenously (IV) and subcutaneous (SC) at 1.1 mg/kg to eight healthy lactating dairy does.

Trial 3 Trial 3 Trial 4 Trial 4
Parent drug or metabolite PK parameter Mean ± SD (IV) Mean ± SD (SC) Mean ± SD (IV) Mean ± SD (SC)
Flunixin Cmax (μg/ml) 7.2346 ± 3.3252 0.8383 ± 0.2372 7.6909 ± 1.3452 1.4341 ± 0.2237
Tmax (h) NA 1.28 ± 0.31 NA 1.17 ± 0.44
T1/2Z (h) 4.56 ± 2.70 3.77 ± 5.69 4.35 ± 2.43 3.03 ± 1.57
Z (h−1) 0.122 ± 0.08 0.11 ± 0.13 0.13 ± 0.08 0.19 ± 0.09
AUCinf (h*μg/ml) 4.319 ± 1.350 3.059 ± 0.619 6.335 ± 0.993 5.672 ± 1.185
AUC%ext (%) 0.28 ±0.27 0.28 ± 0.26 0.057 ± 0.16 0.035 ± 0.053
Vz, Vz/F (ml/kg) 1,945 ± 1,357 2,518 ± 3,295 1,222 ± 611 939 ± 499
Cl, CL/F (ml/kg/h) 265 ± 78.4 365 ± 59.1 176 ± 29.4 199 ± 57.8
AUMCinf (h*h*μg/ml) 7.842 ± 1.767 11.790 ± 1.903 15.971 ± 6.142 22.503 ± 8.551
MRTinf (h) 1.83 ± 0.62 3.88 ± 0.61 2.38 ± 1.03 3.99 ± 0.86
Ebody 3.55 ± 1.00
F (%) 74.0 ± 20.0
5-OH Cmax (μg/ml) 0.1341 ± 0.0245 0.0552 ± 0.0185 0.1385 ± 0.0343 0.0605 ± 0.0153
Tmax (h) 0.25 ± 0.18 1.33 ± 0.42 0.19 ± 0.04 1.65 ± 0.26
T1/2Z (h) 3.65 ± 3.24 3.34 ± 1.05 3.68 ± 5.43 2.99 ± 3.23
Z (h−1) 0.14 ± 0.09 0.19 ± 0.08 0.12 ± 0.09 0.16 ± 0.14
AUCinf (h*μg/ml) 0.2216 ± 0.0408 0.2372 ± 0.0673 0.2170 ± 0.0564 0.2631 ± 0.0780
Vz, Vz/F (ml/kg) 30,209 ± 22,990 24,200 ± 10,441 32,388 ± 38,001 22,395 ± 34,303
Cl, CL/F (ml/kg/h) 5,034 ± 894 4,785 ± 1,229 5,205 ± 1,196 4,384 ± 1,818
AUMCinf (h*h*μg/ml) 0.745 ± 0.251 1.007 ± 0.233 0.694 ± 0.306 1.129 ± 0.487
MRTinf (h) 3.34 ± 0.90 3.34 ± 0.89 3.10 ± 1.08 4.36 ± 1.13

AUCinf, area under the concentration curve from time 0 to infinity; AUC%ext (%), area under the concentration curve extrapolated; AUMCinf, area under the moment curve from time zero to infinity; Cmax, maximum concentration observed; CL, observed clearance; MRTinf, mean residence time; Ebody, Extraction ratio; F, bioavailability; T1/2Z, half-life of terminal elimination; Tmax, observed time to maximum concentration; Vz, volume of distribution; Z, terminal elimination constant.

Trial 3: Lactating dairy does (n = 8). Trial 4: Lactating dairy does (n = 8).